


A Practical, Selectivity Based Hydrophilic Interaction Liquid Chromatography (HILIC) Method Development Protocol

Alan P McKeown

Advanced Chromatography Technologies Ltd, 1 Berry Street, Aberdeen, Scotland, AB25 1HF UK


1. Introduction

- Exploring **chromatographic selectivity** is a **powerful** approach for LC method development.
- Efficient **method development** requires a **logical exploration** of the key chromatographic parameters affecting selectivity.
- Rationally designed method development strategies **assess key parameters** and allow **well informed decision making** leading to **robust stationary phase / mobile phase selection**.
- Method development strategies based on **column / mobile phase screening** and optimisation are commonly utilised for reversed phase.
- For **HILIC**, such strategies are **less common / less well defined**.
- This poster demonstrates a **simple, step-by-step approach** to HILIC method development, based on the **concept of exploring column selectivity**.




2. Selectivity in HILIC

- In HILIC, the **column stationary phase** has a significant effect on chromatographic **selectivity**.
- The **ACE HILIC range** consists of three complementary phases **specifically designed to offer maximum selectivity differences** – ideal for method development:




- Mobile phase pH** is also a powerful parameter and can affect ionisation of analytes and the **stationary phase itself**.
- Method development strategies based on **screening different stationary phases and mobile phase pH** are therefore the optimum choice.
- Buffer concentration and temperature** are **less influential**, however can be used to **fine-tune methods**.

3. Effect of stationary phase and pH



4. ACE MD Protocol




5. Screening Conditions

- Isocratic and gradient screening** is performed as follows:

Table 1	
Column	ACE HILIC-A, ACE HILIC-B and ACE HILIC-N, 150 x 4.6 mm
Isocratic screening	10 mM ammonium formate in MeCN/H ₂ O (90:10 v/v)
Gradient screening	Ammonium formate at pH 3.0, 4.7 or 6.0.
	Line A: 10 mM ammonium formate in MeCN/H ₂ O (94:6 v/v) Line B: 10 mM ammonium formate in MeCN/H ₂ O (50:50 v/v) Ammonium formate at pH 3.0, 4.7 or 6.0.
Gradient:	Time (mins.)
	%B
	0
	15
	20
	21
Flow rate	1.5 mL/min
	Temperature
	25 °C
Detection	Dependent on sample

6. Example 1: Caffeine and Related Substances


- The **screening protocol** was used to develop a **HILIC method** for caffeine and related substances.
- All analytes are **polar neutral** with **negative logP values**.



- The mixture was screened on the **ACE HILIC-A, HILIC-B and HILIC-N phases at pH 3.0 and 4.7**.

7. Caffeine and Related Substances: Gradient Screen

- The **HILIC-N at pH 3.0** provided the most potential for a full separation.




Gradient screen of caffeine and related compounds at pH 3.0 and 4.7. Conditions as per table 1. Sample: 1. Caffeine, 2. Theophylline, 3. Theobromine, 4. Xanthine, 5. Hypoxanthine


First published in Chromatography Today, Volume 8, Issue 4, Nov/Dec 2015

8. Caffeine and Related Substances: Optimisation

- Isocratic or gradient mode**
- Isocratic** conditions were assessed and found to **increase the retention of later eluting compounds** but **failed to improve resolution** between the critical pair.




- Effect of Temperature**
- Reducing the temperature** was found to **improve the resolution** of both impurity peak pairs.



9. Caffeine and Related Substances: Final Method


- Reduced temperature** was utilised to achieve separation of the mixture on the **ACE 5 HILIC-N at pH 3.0**.
- A **small increase in acetonitrile** in the **gradient starting conditions** was also found to be beneficial



First published in Chromatography Today, Volume 8, Issue 4, Nov/Dec 2015

10. Example 2: MMA and Succinic Acid


- Elevated levels of methylmalonic acid (MMA)** in blood/urine is routinely tested for as an **indicator of vitamin B12 deficiency**.
- The **isobaric species succinic acid** may be present in biomatrices at **concentrations up to 50x that of MMA**.
- Chromatographic **separation** of these two components with **good retention** to **eliminate matrix interference** is therefore essential for **accurate determination**.
- Physico-chemical properties are **similar** and **suitable** for HILIC mode



- The two compounds were **screened** on the three **ACE HILIC phases**.
- The two acids were predicted to possess a **single negative charge at pH 3.0** and a **double negative charge at pH 6.0**, therefore these two mobile phase pH's were selected for screening

11. Example 2: MMA and Succinic Acid

- Very strong retention** was observed at **pH 6.0** on all phases (data not shown).
- At pH 3.0, the analytes proved **difficult to separate** on the **ACE HILIC-N** and **ACE HILIC-A** phases due to **similar analyte properties**.
- The **ACE HILIC-B** provided **additional retention and selectivity** for the two analytes.
- Use of the **screening protocol** provided a separation of these challenging analytes on the **ACE HILIC-B** phase with **no further development required**.



12. Summary

- A **systematic and rationally designed method development strategy** can aid in **streamlining the method development process**.
- In **HILIC**, column **stationary phase** and **mobile phase pH** are the most **critical parameters** affecting selectivity.
- The **step-by-step method development strategy** proposed in this poster therefore provides a powerful means by which to **probe selectivity** of a new application.
- The **ACE HILIC-A, HILIC-B and HILIC-N** phases have been shown to provide **complimentary selectivity**, ideal for **method development**.
- Screening** an analyte mixture on these three phases has been demonstrated as an effective method development strategy for **selecting an appropriate stationary phase/mobile phase combination**.
- Optimisation** can be achieved by altering parameters such as **ionic strength**, **% organic** and **temperature**.

ACE® is a registered trademark of Advanced Chromatography Technologies Limited. ACE UltraCore™ and EBT™ are trademarks of Advanced Chromatography Technologies Limited.